Pharmacogenetics in epilepsy treatment: Sense or nonsense?

Personalized Medicine

Volumn 5, Issue 2, 2008, Pages 123-131

  Depondt, Chantal ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Allele; Antiepileptic drug; Association; Epilepsy; Pharmacogenetics; Response; SNP

Indexed keywords

ABC TRANSPORTER A1; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; FELBAMATE; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 70; HLA B ANTIGEN; HLA DQ2 ANTIGEN; HLA DR3 ANTIGEN; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN 1; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VIGABATRIN;

APLASTIC ANEMIA; CHINA; COGNITIVE DEFECT; DIZZINESS; DOSE RESPONSE; DRESS SYNDROME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; EPILEPSY; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; HUMAN; LANGUAGE DISABILITY; LOW DRUG DOSE; NEUROTOXICITY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SEIZURE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; VISUAL FIELD DEFECT;

EID: 42649116807     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.2.123     Document Type: Review

References (64)

1. Shorvon SD: The Treatment of Epilepsy. Blackwell Publishers, Oxford, UK (2004).
2. Devinsky O: Patients with refractory seizures. N. Engl. J. Med. 340(20), 1565-1570 (1999).
3. Begley CE, Beghi E: The economic cost of epilepsy: a review of the literature. Epilepsia 43(Suppl. 4), 3-9 (2002).
4. Goldstein DB, Tate SK, Sisodiya SM: Pharmacogenetics goes genomic. Nat. Rev. Genet. 4(12), 937-947 (2003).
5. Berg AT, Kelly MM: Defining intractability: comparisons among published definitions. Epilepsia 47(2), 431-436 (2006).
6. Remy S, Beck H: Molecular and cellular mechanisms of pharmacoresistance in epilepsy, Brain 129(Pt 1). 18-35 (2006).
7. Schinkel AH: Pharmacological insights from P-glycoprotein knockout mice. Int. J. Clin. Pbarmacol. Ther. 36(1), 9-13 (1998).
8. Loscher W, Potschka H: Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301(1), 7-14 (2002).
9. Sisodiya SM. Lin WR, Harding BN, Squier MV, Tliorn M: Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125(Pt 1). 22-31 (2002).
10. Kimichi-Sarfaty C. Oh JM, Kim IW et al.: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811). 525-528 (2007).
11. Siddiqui A. Kerb R, Weale ME et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348(15), 1442-1448 (2003).
12. Hung CC, Tai JJ. Lin CJ, Lee MJ, Liou HH: Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 6(4), 411-417 (2005).
13. Kim DW, Kim M, Lee SK, Kang R, Lee SY: Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 15(5), 344-347 (2006).
14. Kim YO, Kim MK, Woo YJ et al.: Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 15(1), 67-72 (2006).
15. Leschziner G, Jorgensen AL, Andrew T et al.: Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol. 5(8), 668-676 (2006).
16. Seo T, Ishitsu T, Ueda N et al.: ABCB1 polymorphisms influence the response to antlepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7(4), 551-561 (2006).
17. Sills GJ, Mohanraj R, Butler E et al.: Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46(5), 643-647 (2005).
18. Tan NC, Heron SE, Scheffer IE et al.: Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63(6), 1090-1092 (2004).
19. Zimprich F, Sunder-Plassmann R, Stogmann E et al.: Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63(6), 1087-1089 (2004).
20. Shahwan A, Murphy K, Doherty C et al.: The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res. 73(2), 192-198 (2007).
21. Awasthi S, Hallene KL, Fazio V et al.: RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci. 6, 61 (2005).
22. Soranzo N, Kelly L, Martinian L et al.: Lack of support for a role for RLIP76 (RALBP 1) in response to treatment or predisposition to epilepsy. Epilepsia 48(4), 674-683 (2007).
23. Daly AK: Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17(1), 27-41 (2003).
24. Kalviainen R, Nousiainen I: Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 15(3), 217-230 (2001).
25. Lee S, Sziklas V, Andermann F et al.: The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 44(3), 339-347 (2003).
26. Uetrecht J: Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov. Today 8(18), 832-837 (2003).
27. Pirmohamed M, Lin K, Chadwick D, Park BK: TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 56(7), 890-896 (2001).
28. Chung WH, Hung SI, Hong HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982), 496 (2004).
29. Hung SI, Chung WH. Jee SH et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4). 297-306 (2006).
30. Man CB, Kwan P, Baum L et al.: Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5), 1015-1018 (2007).
31. Lonjou C. Thomas L, Borot N et al.: A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006).
32. Alfirevic A, Jorgensen AL, Williamson PR et al.: HLA-B locus in Caucasian patients with carbamazepine. hypersensitivity. Pharmacogenomics 7(6), 813-818 (2006).
33. Alfirevic A. Mills T, Harrington P et al.: Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet. Genomics 16(4), 287-296 (20061.
34. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R: Severe phenytoin Intoxication in a subject homozygous for CYP2C9*3. Clin. Pharmacol. Ther. 70(4), 391-394 (2001).
35. Ninomiya H, Mamiya K, Matsuo S et al.: Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther. Drug Monit. 22(2), 230-232 (2000).
36. Tate SK, Depondt C, Sisodiya SM et al.: Genetic predictor of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102(15), 5507-5512 (2005).
37. Aynacioglu AS, Brockmoller J, Bauer S et al.: Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 48(3), 409-415 (1999).
38. Hung CC, Lin CJ. Chen CC, Chang CJ, Liou HH: Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther. Drug Monit. 26(5), 534-540 (2004).
39. Mamiya K,Ieiri I. Shimamoto J etal.: The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39(12), 1317-1323 (1998).
40. Odani A, Hashimoto Y, Otsuki Y et al.: Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin. Phaimacol. Ther. 62(3), 287-292 (1997).
41. van der Weide J, Steijns LS, van Weelden MJ. de Haan K: The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11 (4), 287-291 (2001).
42. Xie HG. Kim RB, Wood AJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
43. Tate SK, Singh R, Hung CC et al.: A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 16(10). 721-726 (2006).
44. Heinzen EL, Yoon W. Tate SK et al.: Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am. J Hum. Genet. 80(5), 876-883 (2007).
45. Healy DG: Case-control studies in the genomic era: a clinician's guide. Lancet Neurol. 5(8), 701-707 (2006).
46. Urquhart BL, Tirona RG, Kim RB: Nuclear receptori and the regulation of drug-metabollzing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin. Pharmacol. 47(5), 566-578 (2007).
47. Bauer B, Yang X, Hartz AM et al.: In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol. Pharmacol. 70(4), 1212-1219 (2006).
48. Ouahchi K, Lindeman N. Lee C: Copy number variants and pharmacogenomics. Pharmacogenamics 7(1), 25-29 (2006).
49. Bracco L, Kearsey J: The relevance of alternative RNA splicing to pharmacogenomics. Trends Biotechnol. 21(8), 346-353 (2003).
50. Jain KK: Applications of AmpliChip CYP450. Mol. Diagn. 9(3), 119-127 (2005).
51. Woelderink A. Ibarreta D, Hopkins MM, Rodriguez-Cerezo E: The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J. 6(1), 3-7 (2006).
52. Need AC, Motulsky AG, Goldstein DB: Priorities and standards in pharmacogenetic research. Nat. Genet. 37(7), 671-681 (2005).
53. Avendano C, Menendez JC: Inhibitors of multidrug resistance to antitumor agents (MDR). Curr. Med. Chem. 9(2), 159-193 (2002).
54. Iannetti P, Spatice A, Parisi P: Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46(6), 967-969 (2005).
55. Newman MJ, Dixon R, Toyonaga B: OC144-093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy. Novartis Found. Symp. 243, 213-226; discussion 226-230, 231-215 (2002).
56. Summers MA, Moore JL, McAuley JW: Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann. Pharmacother. 38(10), 1631-1634 (2004).
57. Fishman MC, Porter JA: Pharmaceuticals: a new grammar for drug discovery. Nature 437(7058), 491-493 (2005).
58. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429 (6990), 464-468 (2004).
59. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5(9), 645-656 (2004).
60. +-coupled amino-acid transporter hPAT1. Br. J. Pbarmacol. 147(3):298-306 (2006).
61. Patsalos PN, Froscher W, Pisani F, van Rijn CM: The importance of drug interactions in epilepsy therapy. Epileasia 43(4), 365-385 (2002).
62. Staines AG, Coughtrie MW, Burchell B: N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J. Pharmacol. Exp. Ther. 311(3), 1131-1137 (2004).
63. Kwan P, Sills GJ, Brodie MJ: The mechanisms of action of commonly used antiepileptic drugs. Pharmacol. Ther. 90(1), 21-34 (2001).
64. Lynch BA, Lambeng N, Nocka K et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA 101 (26), 9861-9866 (2004).